河北医科大学学报 ›› 2022, Vol. 43 ›› Issue (4): 397-401,428.doi: 10.3969/j.issn.1007-3205.2022.04.006

• • 上一篇    下一篇

西格列汀联合氯沙坦钾治疗糖尿病合并高血压的安全性、有效性分析

  

  1. 天津医科大学总医院内分泌与代谢科,天津 300041
  • 出版日期:2022-04-25 发布日期:2022-04-30
  • 作者简介:赵夕琛(1993-),女,陕西宝鸡人,天津医科大学总医院主治医师,医学硕士,从事内分泌与代谢疾病诊治研究。
  • 基金资助:

    天津市卫生健康科技项目(ZC201906)

Safety and efficacy of siglitine combined with losartan potassium in the treatment of diabetes mellitus complicated by hypertension

  1. Department of Endocrinology and Metabolism, General Hospital of Tianjin Medical University, Tianjin 300041, China
  • Online:2022-04-25 Published:2022-04-30

摘要:

目的  探究西格列汀联合氯沙坦钾对糖尿病合并高血压患者血管生成素样蛋白2angiopoietin-like protein 2Angptl2)水平及糖代谢的影响。

方法  选取我院接诊的糖尿病合并高血压患者142例作为研究对象,按照治疗方法不同将其分为西格列汀组(67例,采用西格列汀进行治疗)和联合治疗组(75例,采用西格列汀联合氯沙坦钾进行治疗)。观察两组颈动脉超声检查结果、血压、血管僵硬度、糖代谢、肾功能指标及治疗效果;酶联免疫吸附试验(enzyme linked immunosorbent assayELISA)检测血清Angptl2、血管内皮功能。

结果  联合治疗组治疗后内膜中层厚度(medium lining thicknessIMT)、Crouse积分、斑块检出率,血压、血管僵硬度,糖代谢、肾功能指标,血清Angptl2、血管内皮功能水平较低(P0.05)。联合治疗组治疗后治疗总有效率较高(P0.05)。与西格列汀组相比,联合治疗组总不良反应发生率略高,但两组比较差异无统计学意义(P0.05)。

结论  西格列汀联合氯沙坦钾可有效改善糖尿病合并高血压患者临床症状,降低Angptl2水平,促进糖代谢恢复正常,取得良好的效果、不良反应少,值得推广。

关键词:

糖尿病, 高血压, 西格列汀, 氯沙坦钾

Abstract:

Objective  To explore the effects of siglitine combined with losartan potassium on angiogenesis-like protein 2(Angptl2) and glucose metabolism in diabetic patients with hypertension.

Methods  A total of 142 patients with diabetes mellitus and hypertension were selected as the subjects. According to the treatment methods, they were divided into siglitatin group(n=67, treated with siglitatin) and combination treatment group(n=75, treated with siglitatin combined with losartan potassium). The results of carotid ultrasound examination, blood pressure, vascular stiffness, glucose metabolism, renal function index and therapeutic effect were observed in the two groups, and the serum Angptl2 and vascular endothelial function was detected by enzyme linked immunosorbent assay(ELISA).

Results  In the combination treatment group, endometrial intermediate thickness(IMT), Crouse score, plaque detection rate, blood pressure, vascular stiffness, glucose metabolism, renal function indexes, and the levels of serum Angptl2 and vascular endothelial function were lower after treatment(P0.05). Total effective rate was higher in combination treatment group after treatment(P0.05). The total incidence of adverse reactions was slightly higher in combination treatment group than in the siglitine group, but there was no statistical difference between two groups(P0.05).

Conclusion  Siglitine and losartan potassium can effectively improve the clinical symptoms of patients with diabetes combined with hypertension, reduce the Angptl2 level, promote the normalization of sugar metabolism, and achieve good results with few adverse reactions. Therefore, it is worthy of promotion and popularization.

Key words: diabetes mellitus; hypertension; siglitine, losartan potassium